Atrandi Biosciences has raised $25 million in a Series A funding round led by Lux Capital, with participation from Vsquared Ventures, Practica Capital, Metaplanet, and CRIDS Capital. The company plans to use the funds to develop new products based on its semi-permeable capsule (SPC) technology as well as to set up an office in Boston which will allow the company to better serve its U.S.

Atrandi Biosciences 在由 Lux Capital 领投的 A 轮融资中筹集了 2500 万美元，Vsquared Ventures、Practica Capital、Metaplanet 和 CRIDS Capital 参与了本轮融资。该公司计划利用这笔资金开发基于其半透性胶囊 (SPC) 技术的新产品，并在波士顿设立办事处，以便公司更好地服务其美国客户。

customer base. .

客户基础。

Atrandi, which means “you discover” in Lithuanian, was launched in 2016 to address technological challenges associated with single-cell analysis. As Juozas Nainys, PhD, Atrandi’s CEO & co-founder, explained, the company was launched “to bridge a fundamental gap in biological research

Atrandi，立陶宛语中意为“你发现”，于2016年推出，旨在应对与单细胞分析相关的技术挑战。正如Atrandi的首席执行官兼联合创始人尤奥扎斯·奈尼斯博士所解释的那样，公司成立的目的是“填补生物研究中的一个基本空白”。

—

—

the need for high-throughput, scalable technologies to manipulate and analyze single cells with precision.” Furthermore, “our SPC technology is a fundamental breakthrough born from a need to overcome the limitations of existing single-cell analysis tools, giving researchers the possibility to generate rich datasets with an unprecedented combination of throughput, multimodality and data quality.” .

对高通量、可扩展技术的需求，以精确操控和分析单细胞。”此外，“我们的SPC技术是一项根本性的突破，源于克服现有单细胞分析工具局限性的需求，使研究人员能够以前所未有的通量、多模态和数据质量组合生成丰富的数据集。

Atrandi will use some of the funds from its Series A to extend its offerings for DNA analysis from single cells, Nainys told

纳伊尼斯表示，Atrandi 将利用其 A 轮融资的部分资金，将其单细胞 DNA 分析服务扩展至更多领域。

GEN

生成

. The company already has a solution for microbial cells and expects to launch an option that works for eukaryotic cells later this year. They will be able to support whole genome analysis as well as more targeted analysis of single cells. Next year, Atrandi will focus on developing products for multi-omic analysis—specifically DNA and RNA analysis from single cells. .

该公司已经拥有针对微生物细胞的解决方案，并预计在今年晚些时候推出适用于真核细胞的选项。他们将能够支持全基因组分析以及对单细胞更有针对性的分析。明年，Atrandi 将专注于开发用于多组学分析的产品，特别是来自单细胞的 DNA 和 RNA 分析。

Designed for high-throughput single-cell research, Atrandi’s SPCs are aqueous compartments that are enclosed by a semi-permeable shell. They are designed to isolate single cells and nucleic acids while enabling the exchange of small molecules like enzymes and nutrients. The ability to exchange materials is an important part of SPCs value proposition for single cells and something that sets Atrandi’s technology apart from current droplet microfluidics technologies, according to Nainys.

Atrandi的SPC专为高通量单细胞研究设计，是被半透膜包裹的水相隔室。它们旨在隔离单细胞和核酸，同时允许小分子（如酶和营养物）的交换。据Nainys称，实现物质交换的能力是SPC在单细胞研究中的重要价值主张，也是Atrandi技术区别于当前液滴微流控技术的关键所在。

Typically, “once you form a droplet you can add reagents to it … but you can never remove [them],” he explained. “That’s very limiting [because] there are so many different molecular biology reactions that just do not work together or require specific pH [and] buffers.” .

他解释说：“通常情况下，‘一旦你形成了一个液滴，你可以向其中添加试剂……但你永远无法移除它们。’这非常有限制性，因为有许多不同的分子生物学反应彼此不兼容，或者需要特定的 pH 值和缓冲液。”

Nainys interest in single-cell technologies predates Atrandi’s founding. During his PhD, he worked in a laboratory focused on developing single-cell RNA sequencing technologies. “The single-cell revolution was really brought about by droplet microfluidics,” he said. “The lab that I joined specialized in droplet microfluidics and as experts in that particular technology, we saw that there are … a lot of things that can not be done in droplets.” That led him and Atrandi’s co-founders to launch the company in 2016 with an eye toward developing and commercializing SPCs as well as instruments for generating them..

纳伊尼对单细胞技术的兴趣可以追溯到阿特兰迪公司成立之前。在攻读博士学位期间，他在一个专注于开发单细胞RNA测序技术的实验室工作。“单细胞革命实际上是由液滴微流控技术带来的，”他说。“我加入的实验室专门研究液滴微流控技术，作为该技术的专家，我们发现……液滴中有很多事情无法实现。”这促使他和阿特兰迪的共同创始人在2016年成立了公司，目标是开发和商业化SPC以及用于生成它们的仪器。

To date, Atrandi has released three products based on its technology. The first of these is the Flux Microfluidic Device, a user-friendly system designed for high-throughput single-cell isolation into SPCs. The primary goal of this system was to “make the compartmentalization of the sample as seamless as possible so it’s really a push button,” Nainys said.

迄今为止，Atrandi 已基于其技术发布了三款产品。其中首款是 Flux 微流控设备，这是一款旨在将高通量单细胞分离到 SPC 的用户友好型系统。Nainys 表示，该系统的主要目标是“让样本的区室化尽可能无缝，真正做到一键操作”。

“It’s more for a broader audience that doesn’t want to tinker with the technology.”.

“它更适合那些不想对技术进行调整的广大受众。”

The two other products in Atrandi’s portfolio are the Onyx Droplet Generator, a microfluidic platform designed for high-throughput single-cell and single-molecule applications, and the Styx High-Throughput Screening Platform, which is designed for fluorescence-activated droplet sorting. These platforms are designed for users who want more control of their workflows and the ability to adjust different parameters as needed, Nainys said.

Atrandi 产品组合中的另外两个产品是 Onyx 液滴生成器（一个专为高通量单细胞和单分子应用设计的微流控平台）和 Styx 高通量筛选平台（专为荧光激活液滴分选设计）。Nainys 表示，这些平台专为希望对工作流程有更多控制并能够根据需要调整不同参数的用户而设计。

They are compatible with SPCs as well as droplets. Additionally, “we also worked hard to make sure that the capsules integrate well with any readout method” including sequencing instruments, microscopy, and mass spectrometers. .

它们与SPC和液滴兼容。此外，“我们还努力确保胶囊与任何读取方法都能很好地结合”，包括测序仪、显微镜和质谱仪。

So far, Atrandi has installed over 150 devices in labs in Europe, North America, and South Korea where they are used for a wide range of applications. About half of its customers are based in U.S. laboratories. People are using the solutions in different ways including studies in oncology, immunology, and microbiology, Nainys said.

到目前为止，Atrandi已经在欧洲、北美和韩国的实验室安装了150多台设备，这些设备被用于广泛的应用。大约一半的客户来自美国的实验室。Nainys表示，人们正在以不同的方式使用这些解决方案，包括在肿瘤学、免疫学和微生物学领域的研究。

“It really is all over the map but at the end of the day it’s analyzing single cells as part of a complex biological system.” .

“它确实是无处不在，但归根结底，它是将单个细胞作为复杂生物系统的一部分进行分析。”

News

新闻